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<H1>INTRODUCTION
Dystroglycanopathies are a group of clinically heterogeneous inherited neuromuscular disorders caused by reduced glycosylation of α-dystroglycan (α-DG) [1] .
Mutations in the guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B (GMPPB) gene resulting in reduced α-DG glycosylation were first described by Carss et al. in 2013, in muscle biopsies of patients with dystroglycanopathy [2] . Subsequently, a study on zebrafish showed that GMPPB knockdown caused structural muscle defects with decreased motility, eye abnormalities, and reduced glycosylation of α-DG, indicating that the GMPPB gene is responsible for dystroglycanopathies [2] . To date, at least 72 patients with GMPPB gene mutations have been reported [3] . The phenotypes of GMPPB mutations are extremely heterogeneous, including adult-onset limb-girdle muscular dystrophy type 2T (LGMD2T), congenital muscular dystrophies (CMD), isolated rhabdomyolysis and congenital myasthenic syndrome (CMS) with/without elevated serum creatine kinase (CK) level, intellectual disability, epilepsy, eye diseases, and heart and brain abnormalities [2, [4] [5] [6] . Herein, we report the case of a 29-year-old Chinese male presenting with LGMD who was found to have two heterozygous GMPPB mutations.
<H1>CASE REPORT
This study was approved by the Institutional Review Board of our hospital. Written informed consent was obtained from the patient for the use and publication of his data for research purposes.
A 29-year-old Chinese male arrived to our hospital with a complaint of long-term progressive limb weakness. At the age of 10, he had difficulty climbing stairs, could not run fast, and became fatigued easily. The symptoms gradually became more severe after the age of 16. He had no history of other diseases. He was the second child of his non-consanguineous parents.
His parents and elder brother were without similar symptoms. On examination, he had a (p.P116S). In addition, both of the variants were rare and not polymorphisms. Sanger sequencing of his parents suggested that the c.553C>T mutation was maternally inherited and that the c.346C>T mutation was paternally inherited (Figure 2 ). Based on these data, his clinical history, and physical examination findings the patient was diagnosed with LGMD2T.
He was treated with B-complex vitamins (neurotrophic therapy), but his symptoms were only minimally affected.
<H1>DISCUSSION
α-DG is a cell membrane protein located on muscle cells and on Schwann cells in the nervous system that undergoes extensive N-linked and O-linked glycosylation. Glycosylation is required so that α-DG can interact with other extracellular proteins. One of the results of defective α-DG glycosylation is reduced muscle contraction [7] . Thus, mutations in α-DG glycosylation-associated genes may lead to dystroglycanopathies. Currently, 18 genes involved in α-DG glycosylation have been identified, including FKTN, POMGnT1, and
GMPPB is a cytoplasmic enzyme that catalyzes the formation of GDP-mannose, a key substrate for several glycosylation pathways, including O-mannosylation of α-DG [2] .
Mutations in the GMPPB gene have recently been identified to cause α-DG glycosylation disorders [2] . Since GMPPB mutations causing disorders of α-DG glycosylation were first described by Carss et al. in 2013, 72 cases have been reported in the literature (Table S1) heterozygous GMPPB mutations, including c.1070G>A, c.1018G>A, c.C877T, and c.C966A [5] . Of them, c.1070G>A was found in all 5 patients [5] . Our patient was found to have compound heterozygous GMPPB mutations. The homozygous missense mutation c.553C>T has been reported in two Mexican, one Egyptian [2] , and three Spanish patients [16] . The mutation changes the highly conserved arginine to cysteine (p.R185C). The 185 th amino acid, arginine, is conserved throughout several species, including humans, chimpanzees, mice, zebrafish, Drosophila, and Caenorhabditis elegans, indicating its functional importance [2] .
Previous studies have shown that patients homozygous for the c.553C>T mutation present with phenotypes including CMD, LGMD/CMS overlap syndromes, and LGMD (as young as 2.5 years old) [2] , cataracts, mental retardation, epilepsy, and elevated serum CK levels [2, 16] .
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The symptoms in our patient were relatively mild. The onset of LGMD was at 10 years of age, and he had no intellectual disability or eye disease. However, his serum CK level was elevated, which is consistent with previous studies [2, 16] . The discrepancy in phenotypes might be attributed to the compound heterozygous mutations in our patient; however, further investigation is needed to examine this finding. The other missense mutation (c.346C>T, p.P116S) has not been reported in previous studies; this mutation changes the highly conserved proline (116 th amino acid) to serine.
LGMD is the most common phenotype of GMPPB-associated dystroglycanopathies [3] [4] [5] [6] [8] [9] [10] [11] [12] [13] [14] [15] . In 2015, Belaya et al. reported that some patients with GMPPB mutations present with CMS, defined as decreased compound muscle action potentials on repetitive nerve stimulation on electromyography [4] . This finding suggests that the neuromuscular junctions from the central to peripheral nervous system may be affected and that electromyography examination for patients with GMPPB mutations should include repetitive nerve stimulation tests. Even though our patient experienced severe fatigue, he did not exhibit a decrease of compound muscle action potentials on repetitive nerve stimulation.
In summary, we have reported a novel GMPPB mutation in a Chinese male with LGMD. This case provides additional information regarding the phenotypic spectrum of GMPPB mutations in the Chinese population.
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